impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Full Papers

 

Efficacy and safety of mycophenolate mofetil and tacrolimus combination therapy in patients with lupus nephritis: a nationwide multicentre study

1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16

 

  1. Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea.
  2. Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea.
  3. Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea.
  4. Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea.
  5. Division of Rheumatology, Department of Internal Medicine, Dong-A University Hospital, Busan, Republic of Korea.
  6. Division of Rheumatology, Department of Internal Medicine, Catholic University of Daegu, School of Medicine, Daegu, Republic of Korea.
  7. Division of Rheumatology, Department of Internal Medicine, Bundang CHA Medical Center, Seongnam, Republic of Korea.
  8. Division of Rheumatology, Department of Internal Medicine, Chosun University Medical School, Gwangju, Republic of Korea.
  9. Department of Rheumatology, Hanyang University Guri Hospital, Guri, Republic of Korea.
  10. Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  11. Division of Rheumatology, Department of Internal Medicine, Kyung Hee University Medical Center, Seoul, Republic of Korea.
  12. Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  13. Division of Rheumatology, Department of Internal Medicine, St. Vincent Hospital, Suwon, Republic of Korea.
  14. Department of Rheumatology, Ajou University School of Medicine, Suwon, Republic of Korea.
  15. Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea.
  16. Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea. shinseok@chonnam.ac.kr

CER11121
2019 Vol.37, N°1
PI 0089, PF 0096
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 29998829 [PubMed]

Received: 21/01/2018
Accepted : 16/04/2018
In Press: 14/06/2018
Published: 18/01/2019

Abstract

OBJECTIVES:
Recent studies have shown that a combination treatment of mycophenolate mofetil (MMF) and tacrolimus (TAC) may be an option for lupus nephritis (LN) patients that do not adequately respond to initial treatment. We evaluated the efficacy and safety of the combination treatment of MMF and TAC in LN patients with suboptimal response to prior MMF or TAC treatments.
METHODS:
In this multicentre study, we retrospectively enrolled 62 patients with class III, IV, or V LN who inadequately responded to MMF or TAC treatment. Those patients were then treated with a combination of MMF and TAC for 6 months. The primary outcome was complete remission (CR) at 6 months, and secondary outcomes included overall response and adverse events.
RESULTS:
After 6 months of treatment with the drug combination, CR was achieved in 14 of 62 patients (22.6%), and 35 (56.5%) patients responded. A significant reduction in proteinuria and lupus disease activity score was observable after 3 months. After 1 year, the CR rate increased to 36.4% (20 of 55 patients), and the overall response rate (n=38, 69.1%) also increased from 6 months. Twenty-one patients reported 29 adverse events, including severe infection requiring hospitalisation (n=3, 10.3%), infection not requiring hospitalisation (n=2, 6.9%), and herpes zoster (n=4, 13.8%).
CONCLUSIONS:
Our findings suggest that a combined MMF and TAC treatment, with a favourable adverse-event profile, may be a beneficial option for LN patients with inadequate response to either MMF or TAC treatments.

Rheumatology Article